Skip to content
Friday, November 20, 2026
Responsive Menu
Home
Healthcare Newsdesk
The Latest UK Healthcare News brought to you by NTSI
Search
Search
Home
Care Home News
Carers
Medicine & Clinical Practice
Arthritis
Brain Conditions
Cancer
Colds and Flu
Diabetes
Diet & Exercise
Eyecare
Menopause
Mens Health
Mental Wellbeing
Psychology
Rare Medical Conditions
Smoking
Women’s Health
Physiotherapy
Private Practice
Recruitment
Wellbeing at Work
Home
Clinical News
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
Clinical News
Cost-effectiveness of camrelizumab combined with chemotherapy in the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma in China
December 19, 2023
Articles From The BMJ
Post navigation
Comparing the long-term outcomes in chronic coronary syndrome patients with prior ST-segment and non-ST-segment elevation myocardial infarction: findings from the TIGRIS registry
Adverse COVID-19 outcomes in American Veterans with age-related macular degeneration: a case-control study